The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1818-1820. DOI 10.1345/aph.1D184
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanvetyanon, T.
Right arrow Articles by Nand, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanvetyanon, T.
Right arrow Articles by Nand, S.

Overcoming Recurrent Cutaneous Reactions from Imatinib Using Once-Weekly Dosing

Tawee Tanvetyanon, MD

Senior Fellow, Division of Hematology/Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL

Sucha Nand, MD

Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Loyola University Medical Center

Reprints: Tawee Tanvetyanon MD, Cardinal Bernardin Cancer Center, 2160 S. First Ave., Maywood, IL 60153-3304, FAX 708/327-3326, ttanve{at}lumc.edu

OBJECTIVE: To describe the use of once-weekly imatinib in a patient who developed recurrent cutaneous reactions associated with imatinib.

CASE SUMMARY: A 65-year-old Asian woman received investigational treatment with imatinib 300 mg/d as maintenance therapy for acute lymphoblastic leukemia. Exfoliative dermatitis developed after 3 weeks of administration. Attempts to resume imatinib at lower dosages, with or without a low-dose corticosteroid, resulted in recurrent reactions. Once-weekly administration of imatinib, however, produced a tolerable, less severe reaction. After the woman had experienced exfoliative dermatitis for 4 months, the reaction subsided and disappeared.

DISCUSSION: Once-weekly administration of imatinib allowed imatinib therapy to continue, and this dosing schedule appeared safe. Patients with severe cutaneous reactions who need to continue imatinib may benefit from this strategy, along with lowering of the dosage and premedication with a corticosteroid.

CONCLUSIONS: In a patient with recurrent cutaneous reactions due to imatinib, a once-weekly dosing schedule was safe, well tolerated, and associated with eventual disappearance of the reaction.

Key Words: acute lymphoblastic leukemia, dermatitis, imatinib

Published Online, October 15, 2003. www.theannals.com, DOI 10.1345/aph.1D184


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
G. Severino, C. Chillotti, R. De Lisa, M. Del Zompo, and R. Ardau
Adverse Reactions During Imatinib and Lansoprazole Treatment in Gastrointestinal Stromal Tumors
Ann. Pharmacother., January 1, 2005; 39(1): 162 - 164.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.